Cepheid Tests Target Rapid ID Of Resistant Bugs, Dovetail With Policy Trends
This article was originally published in The Gray Sheet
Executive Summary
Cepheid launched two tests last week to help hospitals manage challenging infections that can take hold during a patient's stay
You may also be interested in...
Universal Screening For MRSA Does Not Reduce Infections – JAMA Study
Using a rapid molecular assay to screen all surgical patients on admission for a prevalent drug-resistant infection did not reduce the incidence of hospital-acquired infections in a Swiss study involving more than 20,000 patients
Market For Complex Genetic Tests Expands Beyond Specialized Labs
The market for sophisticated gene tests has the potential to greatly expand with the introduction of new "push-button" systems that require less expertise to operate
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.